Navigation Links
Benda Pharmaceutical Files Amendment To Form S-1
Date:5/6/2008

WUHAN, Hubei, China, May 6 /Xinhua-PRNewswire-FirstCall/ -- Benda Pharmaceutical, Inc. (OTC Bulletin Board: BPMA), a China-based pharmaceutical company producing both Gendicine(R), a commercialized gene therapy medicine for the treatment of cancer, and traditional Chinese and conventional medicines, today filed an amendment to the Company's Form S-1 application with the Securities and Exchange Commission ("SEC"). The amendment covers the resale by selling stockholders of up to 17,880,936 shares of common stock, $.001 par value, which includes:

1. 2,106,561 shares of common stock; and

2. 15,774,375 shares of common stock based on 150% of the common stock

issuable upon exercise of outstanding warrants issued at an exercise

price of $0.555 per share in conjunction with the private placements

completed on November 15, 2006 and April 5, 2007.

Mr. Charles Wan, Chief Executive Officer of Benda Pharmaceutical, stated, "We are pleased to file the amendment which takes us one step further to completing our S-1 registration."

Additional information regarding this registration can be found in the Company's Registration Statement on Form S-1/A, as filed with the SEC on May 5, 2008, which can be viewed at http://www.sec.gov .

About Benda Pharmaceutical, Inc.

Benda Pharmaceutical, Inc. ( http://www.bendapharma.com ), a China-based pharmaceutical company, produces traditional Chinese and conventional medicines, as well as Gendicine(R), a commercialized gene therapy medicine for the treatment of cancer.

Safe Harbor Statement

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.


'/>"/>
SOURCE Benda Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
2. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
3. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
4. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
5. Shengtai Pharmaceutical, Inc. Appoints New CFO
6. DermAvance Pharmaceuticals Announces Investment by Ben Franklin Technology Partners of Southeastern Pennsylvania
7. Poniard Pharmaceuticals Announces Upcoming Conference Participation
8. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
9. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
10. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008
11. Biopharmaceutical Alliances: Forging Partnerships That Work
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
(Date:6/23/2016)... ... 2016 , ... Velocity Products, a division of Morris Group, ... exclusively for Okuma CNC machining centers at The International Manufacturing Technology Show, IMTS, ... companies with expertise in toolholding, cutting tools, machining dynamics and distribution, Velocity SMART ...
(Date:6/23/2016)... PUNE, India , June 23, 2016 /PRNewswire/ ... culture media market research report to its pharmaceuticals ... company profiles, product details and much more. ... market spread across 151 pages, profiling 15 companies ... now available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
(Date:6/22/2016)... DUBLIN , June 22, 2016 Research ... and Global Markets" report to their offering. ... $39.4 billion in 2014 from $29.3 billion in 2013. The market ... (CAGR) of 13.8% from 2015 to 2020, increasing from $50.6 billion ... and projected product forecasts during the forecast period (2015 to 2020) ...
Breaking Biology Technology:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:6/1/2016)... June 1, 2016 Favorable Government ... Administration and Criminal Identification to Boost Global Biometrics System ... released TechSci Research report, " Global Biometrics Market ... Forecast and Opportunities, 2011 - 2021", the global biometrics ... 2021, on account of growing security concerns across various ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
Breaking Biology News(10 mins):